**California voters face Proposition 38 on the November 3, 2026 ballot, an initiative statute authorizing $8.4 billion in general obligation bonds for immunology and immunotherapy research.** The measure would allocate half the proceeds to a single University of California-affiliated nonprofit institute selected by the Department of Public Health and the other half through grants to public and nonprofit institutions, with at least half directed to cancer, heart disease, and Alzheimer’s research. It includes requirements for 20% below-average pricing on resulting therapies in California and a 10% revenue return to offset costs. Trader consensus favoring rejection at 58% reflects concerns over the $500–600 million annual General Fund repayment burden for roughly 20 years, the earmarked structure benefiting a specific UCLA-linked entity with substantial prior private philanthropic backing, and limited organized support amid broader fiscal scrutiny of new state debt. Recent reporting has highlighted these allocation and accountability issues as key points of debate ahead of the election.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วCalifornia Immunology Research Bond Proposition
California Immunology Research Bond Proposition
21% โอกาส
ใหม่
ใหม่
Nov 3, 2026
21% โอกาส
ใหม่
ใหม่
Nov 3, 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).**California voters face Proposition 38 on the November 3, 2026 ballot, an initiative statute authorizing $8.4 billion in general obligation bonds for immunology and immunotherapy research.** The measure would allocate half the proceeds to a single University of California-affiliated nonprofit institute selected by the Department of Public Health and the other half through grants to public and nonprofit institutions, with at least half directed to cancer, heart disease, and Alzheimer’s research. It includes requirements for 20% below-average pricing on resulting therapies in California and a 10% revenue return to offset costs. Trader consensus favoring rejection at 58% reflects concerns over the $500–600 million annual General Fund repayment burden for roughly 20 years, the earmarked structure benefiting a specific UCLA-linked entity with substantial prior private philanthropic backing, and limited organized support amid broader fiscal scrutiny of new state debt. Recent reporting has highlighted these allocation and accountability issues as key points of debate ahead of the election.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ตลาดเปิดเมื่อ: Jul 1, 2026, 6:33 PM ET
ปริมาณการซื้อขาย
$2,892วันสิ้นสุด
Nov 3, 2026ตลาดเปิดเมื่อ
Jul 1, 2026, 6:33 PM ETผู้ตัดสินผล
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).**California voters face Proposition 38 on the November 3, 2026 ballot, an initiative statute authorizing $8.4 billion in general obligation bonds for immunology and immunotherapy research.** The measure would allocate half the proceeds to a single University of California-affiliated nonprofit institute selected by the Department of Public Health and the other half through grants to public and nonprofit institutions, with at least half directed to cancer, heart disease, and Alzheimer’s research. It includes requirements for 20% below-average pricing on resulting therapies in California and a 10% revenue return to offset costs. Trader consensus favoring rejection at 58% reflects concerns over the $500–600 million annual General Fund repayment burden for roughly 20 years, the earmarked structure benefiting a specific UCLA-linked entity with substantial prior private philanthropic backing, and limited organized support amid broader fiscal scrutiny of new state debt. Recent reporting has highlighted these allocation and accountability issues as key points of debate ahead of the election.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ปริมาณการซื้อขาย
$2,892วันสิ้นสุด
Nov 3, 2026ตลาดเปิดเมื่อ
Jul 1, 2026, 6:33 PM ETผู้ตัดสินผล
0x65070BE91...**California voters face Proposition 38 on the November 3, 2026 ballot, an initiative statute authorizing $8.4 billion in general obligation bonds for immunology and immunotherapy research.** The measure would allocate half the proceeds to a single University of California-affiliated nonprofit institute selected by the Department of Public Health and the other half through grants to public and nonprofit institutions, with at least half directed to cancer, heart disease, and Alzheimer’s research. It includes requirements for 20% below-average pricing on resulting therapies in California and a 10% revenue return to offset costs. Trader consensus favoring rejection at 58% reflects concerns over the $500–600 million annual General Fund repayment burden for roughly 20 years, the earmarked structure benefiting a specific UCLA-linked entity with substantial prior private philanthropic backing, and limited organized support amid broader fiscal scrutiny of new state debt. Recent reporting has highlighted these allocation and accountability issues as key points of debate ahead of the election.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย